BONE BIOLOGICS CORP (BBLG) Stock Price, Forecast & Analysis
USA - NASDAQ:BBLG - US0980706008 - Common Stock
BBLG Key Statistics, Chart & Performance
The current stock price of BBLG is 1.72 USD. In the past month the price decreased by -31.75%. In the past year, price decreased by -75.91%.
BBLG Latest News, Press Relases and Analysis
BBLG Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.7 | 395.71B | ||
| AMGN | AMGEN INC | 15.35 | 180.75B | ||
| GILD | GILEAD SCIENCES INC | 14.95 | 151.93B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.58 | 109.38B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.97 | 71.42B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 888 | 59.36B | ||
| INSM | INSMED INC | N/A | 40.69B | ||
| NTRA | NATERA INC | N/A | 28.51B | ||
| BIIB | BIOGEN INC | 9.46 | 23.22B | ||
| INCY | INCYTE CORP | 16.83 | 21.11B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.33 | 20.69B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 35.29 | 14.63B |
Related stock screener links
About BBLG
Company Profile
Bone Biologics Corp. operates as a medical device company. The company is headquartered in Burlington, Massachusetts and currently employs 2 full-time employees. The company went IPO on 2015-11-27. The firm is focused on bone regeneration in lumbar spinal fusion using neural epidermal growth factor-like 1 protein (NELL-1) in combination with demineralized bone matrix (DBM), a demineralized bone matrix from the Musculoskeletal Transplant Foundation (MTF) Biologics. The combination NELL-1/DBM medical device is an osteopromotive recombinant protein that provides target specific control over bone regeneration. NELL-1 in combination with DBM. NELL-1, a proprietary skeletal-specific growth factor that is a bone void filler. NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration. The DBM Demineralized Bone Putty provided as part of the convenience kit with NELL-1/DBM is a Class II device. DBM Putty is a matrix composed of processed human cortical bone.
Company Info
BONE BIOLOGICS CORP
2 Burlington Woods Dr Ste 100
Burlington MASSACHUSETTS US
Employees: 2
Phone: 17815524452
BONE BIOLOGICS CORP / BBLG FAQ
Can you describe the business of BONE BIOLOGICS CORP?
Bone Biologics Corp. operates as a medical device company. The company is headquartered in Burlington, Massachusetts and currently employs 2 full-time employees. The company went IPO on 2015-11-27. The firm is focused on bone regeneration in lumbar spinal fusion using neural epidermal growth factor-like 1 protein (NELL-1) in combination with demineralized bone matrix (DBM), a demineralized bone matrix from the Musculoskeletal Transplant Foundation (MTF) Biologics. The combination NELL-1/DBM medical device is an osteopromotive recombinant protein that provides target specific control over bone regeneration. NELL-1 in combination with DBM. NELL-1, a proprietary skeletal-specific growth factor that is a bone void filler. NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration. The DBM Demineralized Bone Putty provided as part of the convenience kit with NELL-1/DBM is a Class II device. DBM Putty is a matrix composed of processed human cortical bone.
What is the stock price of BONE BIOLOGICS CORP today?
The current stock price of BBLG is 1.72 USD.
Does BBLG stock pay dividends?
BBLG does not pay a dividend.
What is the ChartMill technical and fundamental rating of BBLG stock?
BBLG has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Should I buy BBLG stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on BBLG.
What is the employee count for BBLG stock?
BONE BIOLOGICS CORP (BBLG) currently has 2 employees.
What is BONE BIOLOGICS CORP worth?
BONE BIOLOGICS CORP (BBLG) has a market capitalization of 3.10M USD. This makes BBLG a Nano Cap stock.
BBLG Technical Analysis
BBLG Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to BBLG. BBLG has a great financial health rating, but its profitability evaluates not so good.
BBLG Financial Highlights
Over the last trailing twelve months BBLG reported a non-GAAP Earnings per Share(EPS) of -21.15. The EPS increased by 62.21% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -106.15% | ||
| ROE | -112.68% | ||
| Debt/Equity | 0 |
BBLG Forecast & Estimates
7 analysts have analysed BBLG and the average price target is 22.95 USD. This implies a price increase of 1234.3% is expected in the next year compared to the current price of 1.72.